Affinity Asset Advisors LLC Lowers Stock Position in Savara Inc (NASDAQ:SVRA)

Affinity Asset Advisors LLC reduced its position in Savara Inc (NASDAQ:SVRA) by 41.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 410,586 shares of the company’s stock after selling 289,414 shares during the quarter. Affinity Asset Advisors LLC owned about 0.24% of Savara worth $1,260,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new position in shares of Savara in the 4th quarter worth about $64,000. XTX Topco Ltd acquired a new stake in Savara during the 4th quarter worth approximately $34,000. Barclays PLC raised its holdings in Savara by 2.5% in the fourth quarter. Barclays PLC now owns 236,705 shares of the company’s stock valued at $728,000 after buying an additional 5,700 shares during the period. F M Investments LLC purchased a new position in Savara in the fourth quarter valued at approximately $250,000. Finally, Raymond James Financial Inc. acquired a new position in Savara during the fourth quarter valued at approximately $798,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SVRA. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. Finally, Wells Fargo & Company began coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Stock Performance

NASDAQ:SVRA opened at $2.90 on Tuesday. The firm has a 50-day moving average of $2.72 and a two-hundred day moving average of $3.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market cap of $500.64 million, a P/E ratio of -6.74 and a beta of 0.52. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.31.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. On average, research analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.